Inside the research
Zoetis Inc.
ZTS Research profile · latest available data
Price overview
$71.05
▲ +0.78 (+1.1%)
| 52w hi | $144.75 |
|---|---|
| 52w lo | $70.27 |
| Vol | 4.17M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.25
| Short | -0.48 |
|---|---|
| Medium | -0.17 |
| Long | +0.06 |
computed 2026-09-27
Key fundamentals
Zoetis Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $29.36B |
|---|---|
| Enterprise value | $36.94B |
| Trailing P/E | 11.59x |
| Forward P/E | 10.87x |
| EV / EBITDA | 9.09x |
| P / S (ttm) | 3.08x |
| Profit margin | 27.7% |
| Return on equity | 64.9% |
| Revenue growth | -0.2% |
| Earnings growth | +1.2% |
| Debt / equity | 294.00 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.22 | |
| Sector | +0.08 | |
| Technical | -0.34 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Risk Metrics
| Beta vs SPX | 0.57 |
|---|---|
| Corr SPX | 0.28 |
| Annual vol | 32.2% |
| Annual ret | -44.4% |
| Sharpe | -1.38 |
| Max DD | -64.0% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $136.06 |
|---|---|
| High / Low | $185.00 / $95.00 |
| Median | $140.00 |
| Analysts | 17 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 8 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-08 | UBS | → Neutral |
| 2026-05-08 | JP Morgan | → Overweight |
| 2026-04-28 | UBS | → Neutral |
| 2026-04-15 | Citigroup | → Buy |
| 2026-02-13 | B of A Securities | → Neutral |
| 2026-01-22 | Piper Sandler | → Neutral |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Officer / Director Change, Exhibits | read |
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-05-22 | Officer / Director Change, Shareholder Vote | read |
| 2026-05-20 | Reg FD Disclosure, Exhibits | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-02-12 | Earnings Release, Exhibits | read |
| 2026-02-05 | Reg FD Disclosure, Exhibits | read |
| 2025-12-18 | Material Agreement, Material Obligation… | read |
| 2025-12-11 | Reg FD Disclosure, Exhibits | read |
| 2025-12-02 | Other Material Event, Exhibits | read |
| 2025-11-04 | Earnings Release, Exhibits | read |
| 2025-10-28 | Officer / Director Change, Reg FD Disclosure… | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 95.3% |
| HHI | 3,866 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $1.41B | 19.67M |
| Citadel Advisors | $374.46M | 5.21M |
| Capital Research / Capital World | $262.34M | 3.65M |
| Millennium Management | $144.33M | 2.01M |
| Renaissance Technologies | $100.84M | 1.40M |
| AQR Capital Management | $76.96M | 1.07M |
| Fidelity / FMR LLC | $27.35M | 380.57K |
| Bridgewater Associates | $9.64M | 134.20K |
| T. Rowe Price Group | $81.86K | 1.14M |
As of 2026-06-30
Connections
Subsidiarys: zoetis.com
Dividends
| Yield (TTM) | 2.20% |
|---|---|
| $ / share (TTM) | $1.56 |
| 5y CAGR | +20.1% |
Annual dividend per share
| 2021 | $1.00 |
|---|---|
| 2022 | $1.30 |
| 2023 | $1.50 |
| 2024 | $1.73 |
| 2025 | $2.00 |
| 2026 | $1.06 |
SEC Filings
The Long Run
FY 2013–2025 · 12 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $8.54B | +5.9% | |
| Net income | $2.49B | +15.6% | |
| Cash from ops | $2.35B | +15.2% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $70.00 | $71.08 | $69.52 | $71.05 | 4.17M |
| Sep 24 | $71.85 | $72.38 | $69.93 | $70.27 | 3.37M |
| Sep 23 | $72.75 | $73.55 | $71.55 | $71.61 | 3.83M |
| Sep 22 | $71.98 | $73.46 | $71.24 | $72.86 | 3.84M |
| Sep 21 | $72.06 | $72.48 | $70.26 | $71.33 | 3.94M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →